Stock listing

Turquoise:PRML Proteome Sciences plc Share Price

UK listing (Turquoise) of Proteome Sciences plc · home listing LSE:PRM

Follow Proteome Sciences plc into a list and get an email when it puts out news.

Home listing price · LSE:PRM

0.97p GBX (pence) -0.20 (-17.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:PRM

Past year -41.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.97p – 1.30p GBX (pence)Nov 20, 2026
Volume
827,508 sharesNov 20, 2026
Market cap
£3.40M GBPAt the close on Nov 20, 2026 · price × 350.7M shares outstanding
52-week range
0.97p – 4.40p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£3,882 GBPMedian day 58,529 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Proteome Sciences plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:PRM · Home0.97p GBX (pence)-0.20 (-17.1%)827,5081.00p1.30p0.97p1.17pClose on Nov 20, 2026
Frankfurt:PI2€0.0040 EUR+0.0010 (+33.3%)—€0.0040€0.0040€0.0040€0.0030Close on Nov 17, 2026
Munich:PI2€0.0005 EUR-0.0145 (-96.7%)—€0.0140€0.0140€0.0005€0.0150Close on Nov 20, 2026
OTC:PMSNF$0.011 USD+0.001 (+11.0%)9,650$0.021$0.021$0.011$0.010Close on Nov 17, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:PRM · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
0.97p-0.20-17.1%1.00p1.30p0.97p827,508
1.17p-0.06-4.9%1.05p1.33p1.01p3,622
1.23p-0.15-10.9%1.01p1.23p1.01p3,608
1.38p-0.02-1.4%1.10p1.38p1.04p499,557
1.40p+0.04+2.9%1.16p1.40p1.16p96,165
1.36p+0.065+5.0%1.61p1.61p1.36p6,211
1.295p-0.055-4.1%1.68p1.68p1.10p194,817
1.35p-0.105-7.2%1.20p1.69p1.20p139,611
1.455p+0.005+0.3%1.68p1.69p1.21p5,659
1.45p+0.07+5.1%1.69p1.69p1.20p108,266
1.38p-0.075-5.2%1.55p1.55p1.38p137
1.455p+0.005+0.3%1.21p1.68p1.21p9,629
1.45p+0.105+7.8%1.21p1.68p1.21p31,933
1.345p-0.11-7.6%1.21p1.68p1.21p1,545,372
1.455p0.000.0%1.68p1.68p1.244p50,060
1.455p-0.005-0.3%1.69p1.69p1.455p64
1.46p+0.06+4.3%1.22p1.69p1.22p270,196
1.40p-0.05-3.4%1.21p1.69p1.21p1,338
1.45p0.000.0%1.68p1.68p1.45p80,973
1.45p+0.105+7.8%1.21p1.68p1.21p9,133
1.345p0.000.0%1.21p1.49p1.21p20,585
1.345p0.000.0%1.48p1.48p1.345p68
1.345p-0.005-0.4%1.21p1.50p1.21p251,201
1.35p-0.105-7.2%1.70p1.70p1.35p977
1.455p+0.105+7.8%1.21p1.70p1.21p217,021
1.35p0.000.0%1.21p1.49p1.21p51,589
1.35p-0.005-0.4%1.49p1.49p1.21p63,999
1.355p-0.005-0.4%1.21p1.50p1.21p57,906
1.36p0.000.0%1.49p1.50p1.21p115,426
1.36p+0.005+0.4%1.225p1.36p1.225p460
1.355p0.000.0%1.69p1.69p1.27p210,336
1.355p-0.065-4.6%1.60p1.60p1.21p1,135
1.42p-0.035-2.4%1.64p1.70p1.20p10,410
1.455p+0.055+3.9%1.21p1.455p1.21p4,527
1.40p-0.05-3.4%1.501p1.60p1.21p9,103
1.45p0.000.0%1.69p1.69p1.45p4,730
1.45p-0.005-0.3%1.69p1.69p1.21p59,152
1.455p0.000.0%1.20p1.69p1.20p3,770
1.455p+0.055+3.9%1.69p1.69p1.20p537
1.40p+0.075+5.7%1.20p1.69p1.20p107,499
1.325p-0.125-8.6%1.45p1.45p1.325p115,426
1.45p-0.045-3.0%1.69p1.69p1.45p59
1.495p+0.015+1.0%1.69p1.69p1.27p63,616
1.48p0.000.0%1.51p1.69p1.48p2,186
1.48p0.000.0%1.26p1.69p1.26p227,418
1.48p+0.08+5.7%1.27p1.69p1.27p74,178
1.40p-0.05-3.4%1.60p1.70p1.209p726,156
1.45p0.000.0%1.69p1.69p1.259p5,134,541
1.45p+0.05+3.6%1.59p1.60p1.11p869,738
1.40p0.000.0%1.21p1.59p1.20p28,411
1.40p0.000.0%1.21p1.60p1.21p33,588
1.40p0.000.0%1.60p1.60p1.20p726
1.40p0.000.0%1.60p1.60p1.21p232
1.40p0.000.0%1.21p1.59p1.21p2,633
1.40p0.000.0%1.60p1.60p1.40p4,629
1.40p-0.05-3.4%1.21p1.60p1.21p4,662
1.45p+0.05+3.6%1.60p1.60p1.45p392,957
1.40p-0.005-0.4%1.58p1.59p1.21p291,547
1.405p-0.145-9.4%1.31p1.79p1.31p457,661
1.55p-0.025-1.6%1.50p1.85p1.31p603,747
1.575p-0.005-0.3%1.40p1.86p1.40p180,100
1.58p-0.005-0.3%1.31p1.87p1.31p1,171,232
1.585p+0.035+2.3%1.78p1.78p1.417p327,792
1.55p-0.045-2.8%1.456p1.80p1.436p1,077,611
1.595p-0.105-6.2%1.60p1.99p1.425p226,719
1.70p-0.095-5.3%1.60p1.99p1.60p718,017

Splits

1 split · LSE:PRM · every price before a split is adjusted for it

DayRatioWhat
37-for-35Split
Ticker
Turquoise:PRML
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Turquoise
Currency
GBX

What changed lately

Latest news

Appointment of Non-Executive Director

Sep 16, 2026

Closed 1.45p (0.0%) on Sep 16, 2026

Target engagement/chemoproteomics contract

Jun 22, 2026

Closed 1.50p (-0.7%) on Jun 22, 2026

Annual General Meeting Statement

May 14, 2026

Closed 1.85p (0.0%) on May 14, 2026

Holding(s) in Company

Feb 4, 2026

Closed 1.80p (+0.8%) on Feb 4, 2026

Result of Oversubscribed Retail Offer

Jan 28, 2026

Closed 1.91p (-2.3%) on Jan 28, 2026

Retail Offer to raise up to £60,000

Jan 26, 2026

Closed 1.91p (-41.0%) on Jan 26, 2026

Two Further Substantial Contracts for PRM

Jan 6, 2026

Closed 3.41p (+26.3%) on Jan 6, 2026

All Proteome Sciences plc news

Proteome Sciences plc on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
11 in the last 12 months · 217 in all · newest Sep 16, 2026 · oldest 1999
Calls
7 calls with a replay · 7 with a transcript · latest Apr 11, 2025
Decks
1 deck · latest Sep 5, 2006

Where Proteome Sciences plc is listed

ListingExchangeCountryCurrency
LSE:PRM · Home listingLSEUnited KingdomGBX
LS Exchange:935051LS ExchangeGermanyEUR
Lang & Schwarz:935051Lang & SchwarzGermanyEUR
Frankfurt:PI2FrankfurtGermanyEUR
Stuttgart:PI2StuttgartGermanyEUR
Turquoise:PRML · This pageTurquoiseUnited KingdomGBX
AQUIS:PRM.GBAQUISUnited KingdomGBX
Munich:PI2MunichGermanyEUR
OTC:PMSNFOTCUnited StatesUSD

Valuation

EV/sales 4.9× against a median of 0.6×: 7th lowest of 10 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£18.25M GBP
P/E
Loss
EV/sales
4.9×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
−26.8%
Operating margin
−71.0%
Net margin
−81.5%
Debt to equity
Negative equity
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Proteome Sciences plc · LSE:PRMUS$4.45MUS$23.87Mn/a4.9×n/an/a−81.5%n/an/a
VivoSim Labs, Inc. · NASDAQ:VIVSUS$5.29M−US$2.76Mn/a−20.5×n/a0.7×n/a0.1×1.91
Biomerica, Inc. · NASDAQ:BMRAUS$4.97MUS$2.23Mn/a0.5×n/a1.4×−115.5%0.0×0.71
VolitionRx Limited · AMEX:VNRXUS$4.87MUS$9.19Mn/a2.7×n/an/a−698.5%n/a1.52
Boule Diagnostics AB · OMXSTO:BOULUS$4.84MUS$24.70Mn/a0.6×n/a0.3×−4.0%1.3×n/a
BioInfra Co.,Ltd. · KRX:199730US$4.75M−US$509,202n/a−0.0×n/a0.5×−32.3%0.0×n/a
Cardio Diagnostics Holdings Inc. · NASDAQ:CDIOUS$4.74MUS$4.74Mn/a312×n/a0.8×n/a0.0×2.07
Niki BioSolutions, Inc. · NASDAQ:NIKIUS$4.61MUS$4.60Mn/an/an/a0.2×n/a0.1×1.46
Cambridge Nutritional Sciences PLC · LSE:CNSLUS$4.51MUS$1.23Mn/a0.1×n/a0.6×−83.5%0.0×n/a
Immunovia AB · OMXSTO:IMMNOVUS$3.95MUS$2.31Mn/a12.1×n/a6.1×n/a0.4×n/a
SDS Optic Spolka Akcyjna · NEWCONNECT:SDSUS$3.81MUS$3.57Mn/a13.7×n/a11.8×−269.4%0.0×n/a
Median of the othersUS$4.74MUS$2.94M0.6×0.7×−99.5%0.0×1.52

Team and board

Officers

OfficerRole
Christopher PearceExecutive Chairman
Richard DennisChief Commercial Officer and Executive Director

Board

DirectorRole
Christopher PearceExecutive Chairman
Helen SpiceDirector
Ian PikeBoard Member
Martin DiggleBoard Member
Richard DennisChief Commercial Officer and Executive Director

Events

Results days

QuarterResultsShare move
Q2 2025Sep 11, 2025 · Before open0.0%
Quarter to Mar 31, 2025Apr 18, 2025+3.3%
Q1 2023Apr 4, 2023 · Before open+8.3%
Q2 2022Aug 4, 2022+0.7%
Q4 2021Mar 31, 2022−0.8%
Q2 2021Jul 29, 2021−2.6%
Q1 2021Apr 12, 2021+0.7%

Open Events

Decks

Open Decks

Financings

RaiseDateIn US dollars
Retail Offer Shares (new ordinary shares)
Closed: £132,000 raised · GBX 1.75 a share · SP Angel Corporate Finance LLP
Dealers: SP Angel Corporate Finance LLP
Use of proceeds: TMT tag plexing increase, new DXT isotopic plex tags and licence, Solvent Shift workflows, San Diego staff and MS capacity, working capital
Jan 28, 2026US$181,907
Private placement of new ordinary shares
Announced: GBX 1.75 a share
Jan 26, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.76M4.89M5.03M7.78M5.12M4.71M4.63M3.05M3.38M2.74M
Cost of revenue4.76M5.05M3.87M3.01M2.17M2.17M1.70M1.18M1.18M1.20M
Gross profit-1.01M-167.0K1.16M4.77M2.96M2.54M2.93M1.87M2.20M1.55M
Research and development606.0K637.0K376.0K287.0K202.0K355.0K441.0K441.0K1.07M
Selling, general and administrative2.58M3.02M3.27M2.64M2.33M2.04M2.65M3.24M4.01M4.24M
Operating income-2.67M-2.27M-1.47M1.49M512.0K526.0K279.0K-1.37M-1.80M-2.67M
Depreciation and amortization926.0K837.0K484.0K284.0K213.0K165.0K89.0K229.0K332.0K553.0K
EBITDA-1.74M-1.44M-986.0K1.77M725.0K691.0K368.0K-1.14M-1.46M-2.12M
Interest expense925.0K895.0K797.0K473.0K294.0K304.0K335.0K289.0K246.0K257.0K
Income before tax-3.59M-3.25M-2.42M1.25M118.0K245.0K-36.0K-1.66M-2.05M-2.94M
Income tax-530.0K158.0K25.0K-70.0K46.0K-50.0K-185.0K-346.0K444.0K-663.0K
Net income-3.06M-3.41M-2.44M1.32M72.0K295.0K149.0K-1.31M-2.50M-2.28M
Earnings per share, basic-0.01-0.01-0.010.000.000.000.00-0.00-0.01-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents781.0K1.13M2.03M252.9B240.3B193.7B153.4B180.0B175.3B106.9B
Receivables754.0K509.0K1.05M1.57M927.0K1.13M1.67M590.0K1.06M1.34M
Inventory537.0K732.0K837.0K901.0K1.09M878.0K871.0K1.15M946.0K600.0K
Current assets2.07M2.59M4.16M252.9B240.3B193.7B153.4B180.0B175.3B106.9B
Property, plant and equipment1.27M542.0K656.0K56.0K281.0K592.0K
Goodwill4.22M4.22M4.22M3.91B3.89B3.89B3.90B3.91B3.90B3.92B
Total assets8.26M9.21M11.5M1.51T1.38T1.35T1.14T1.13T1.13T1.21T
Accounts payable1.43M639.0K449.0K672.0K375.0K519.0K514.0K372.0K413.0K28.0K
Current liabilities16.6M14.0M12.5M4.62B4.17B3.68B3.47B3.88B3.95B9.36M
Long-term debt0250.0K0166.0K
Total debt15.8M14.5M13.5M139.9B138.6B120.9B128.0B127.2B114.3B119.1B
Total liabilities17.8M15.7M14.5M1.44T1.31T1.28T1.07T1.07T1.07T119.1B
Shareholders' equity-9.53M-6.52M-3.07M68.3B69.1B65.8B64.4B62.6B63.9B64.9B
Shares outstanding295.2M295.2M295.2M309.0M301.9M295.2M295.2M295.2M295.2M236.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-46.0K-826.0K-481.0K2.14M793.0K1.58M-21.5B-14.8B55.5B-31.7B
Capital spending-97.0K-224.0K-237.0K-1.75B-1.72B-1.32B-1.79B-1.40B-1.46B-1.71B
Free cash flow-143.0K-1.05M-718.0K2.14B8.80B-9.07B-23.2B-16.2B54.0B-33.4B
Cash from investing-97.0K-224.0K-424.0K-21.7B4.27B-18.4B-24.0B1.25B3.50B36.7B
Cash from financing-204.0K151.0K-1.06M-209.0K-400.0K-146.0K21.6B17.2B6.30B42.1B
Dividends paid-2.19B-1.93B-1.36B-936.0M
Share buybacks-5.25B-4.13B-1.67B-1.41B-3.08B-4.07B-580.0M-1.73B
Change in cash-347.0K-899.0K-1.97M19.6B49.1B43.5B-27.1B-10.9B60.5B57.6B

Open Financials

Cap table

Built by 6ix from Proteome Sciences plc’s releases · as of Jan 28, 2026

Common shares
350,724,912
Fully diluted
350,724,912

Fully diluted

LineShares
Common shares350,724,912

Share count over time

CountShares
Nov 22, 2026350,724,912

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christopher PearceExecutive Chairman · Since at least Sep 16, 2026
Helen SpiceNon-executive Director · Since at least Sep 16, 2026
Ian PikeBoard Member · Since at least May 14, 2026
Martin DiggleBoard Member · Since at least Dec 23, 2024
Richard DennisChief Commercial Officer and Executive Director · Since at least Sep 16, 2026

Open People

Log in to ask 6ix AI your own questions about Proteome Sciences plc.